Top Markets
#1 Black Phoenix Black Phoenix +354.79%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +76.58%
#4 Gold Park Gold Park +61.59%
#5 OpenEden OpenEden +47.95%
#6 Acurast Acurast +32.33%
#7 BasedHype BasedHype +27.12%
#8 Cryptopia Cryptopia +21.54%
#9 Avantis Avantis +20.48%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +20.03%
Coin of the day
Black Phoenix Black Phoenix
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
OncoSec Medical Incorporated OncoSec Medical Incorporated

OncoSec Medical Incorporated

ONCS
Clasificación en acciones #40489
OncoSec Medical Incorporated is a late-stage immuno-oncology firm dedicated to... OncoSec Medical Incorporated is a late-stage immuno-oncology firm dedicated to creating, advancing, and bringing to market DNA-based therapeutics designed for direct injection into tumors. These therapies aim to activate and amplify the body's anti-cancer immune responses. Its primary therapeutic candidate, ImmunoPulse IL-12 (also known as TAVO), employs an electroporation device to administer DNA encoding interleukin-12 directly into tumors, thereby counteracting the tumor's immunosuppressive environment. OncoSec's clinical pipeline includes several programs for ImmunoPulse IL-12. In combination with KEYTRUDA, it is being investigated for advanced melanoma (under a collaboration and supply agreement, KEYNOTE-695) and for metastatic triple-negative breast cancer (currently in Phase II trials, KEYNOTE-890). Earlier Phase II trials of ImmunoPulse IL-12 combined with KEYTRUDA for advanced or metastatic melanoma, and ImmunoPulse IL-12 as a monotherapy for metastatic melanoma, have both been completed. The company has also completed a Phase II monotherapy biomarker study for advanced or metastatic TNBC. Furthermore, OncoSec is developing its technology for broader application in treating various visceral lesions, including those in the liver, lungs, bladder, and pancreas. Strategic alliances are central to OncoSec's strategy, including clinical trial collaborations with Merck & Co., Inc. for the KEYNOTE-695 and KEYNOTE-890 studies. Research collaborations include Duke University's Center for Applied Therapeutics, exploring TAVO alongside a HER2-plasmid vaccine, and Roswell Park Comprehensive Cancer Center, focusing on intravital microscopy and enhanced IL-12 DNA-plasmids. The company also collaborates with Providence Cancer Institute. Originally incorporated in 2008 as NetVentory Solutions Inc., the company rebranded to OncoSec Medical Incorporated in March 2011 and operates from its headquarters in Pennington, New Jersey.
Precio por acción
$0.2772
Última sincronización: 2023-06-23
Capitalización bursátil
$134.97K
Cambio (1 día)
31.87%
Cambio (1 año)
0.00%
País
US
Comercio OncoSec Medical Incorporated (ONCS)

Categoría

Healthcare
Historial del precio de la acción de OncoSec Medical Incorporated (ONCS)
Precio más alto de cierre: $0.35 el 2023-06-01

Precio más bajo de cierre: $6.69K el 2011-03-01
Historial del precio de la acción de OncoSec Medical Incorporated desde 2011 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2023 -82.06%
2022 -92.24%
2021 -80.26%
2020 189.47%
2019 -72.03%
2018 -58.38%
2017 32.99%
2016 -51.58%
2015 -72.21%
2014 28.92%
2013 44.00%
2012 -1.34%
2011 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $517.18 30.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $857.76 32.66%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $744.96 8.94%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.08K -6.68%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $259.89 16.65%
BE